A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

Local Institution - 0018, Brussels

Local Institution - 0016, Brussels

Local Institution - 0038, Brussels

Local Institution - 0017, Antwerp

Local Institution - 0030, Córdoba

Local Institution - 0031, Donostia / San Sebastian

Local Institution - 0032, Lübeck

Local Institution - 0029, Madrid

Local Institution - 0035, Hanover

Local Institution - 0015, Miami

Local Institution - 0053, Padua

Local Institution - 0034, Essen

Local Institution - 0028, Valencia

Local Institution - 0003, Ann Arbor

Local Institution - 0055, Siena

Local Institution - 0004, Chicago

Local Institution - 0033, Heidelberg

Local Institution - 0023, Tucson

Local Institution - 0002, Los Angeles

Local Institution - 0005, Los Angeles

Local Institution - 0001, Santa Monica

Local Institution - 0040, Nuremberg

Local Institution - 0037, Erlangen

Local Institution - 0008, Morristown

Local Institution - 0044, Ottawa

Local Institution - 0036, Gera

Local Institution - 0026, Barcelona

Local Institution - 0027, Hospitalet de Llobregat - Barcelona